Best Hospitals for Blood Cancer Treatment in Chennai, India

Blood cancers arise from the uncontrolled proliferation of malignant hematopoietic cells within the bone marrow, lymphatic system, or peripheral blood. The three principal categories — leukemia (acute and chronic), lymphoma (Hodgkin and Non-Hodgkin), and multiple myeloma (a plasma cell dyscrasia) — each disrupt normal blood cell production in distinct ways. In leukemia, blasts crowd the marrow, impairing erythropoiesis and thrombopoiesis, leading to anemia, hemorrhagic risk, and severe immunosuppression. Lymphomas originate in lymphoid tissue and can be nodal or extranodal, with Non-Hodgkin lymphoma (NHL) representing over 30 distinct WHO-classified subtypes. Multiple myeloma causes osteolytic bone lesions, hypercalcemia, renal impairment, and recurrent infections via monoclonal immunoglobulin deposition.

• ELIGIBILITY — DIAGNOSIS-CONFIRMED CASES: Patients with histopathologically confirmed blood cancer (bone marrow biopsy, lymph node biopsy, or trephine biopsy) who require induction chemotherapy, consolidation, maintenance therapy, or hematopoietic stem cell transplantation (autologous or allogeneic HSCT).
• NEWLY DIAGNOSED PATIENTS: Those in need of frontline protocol initiation — including pediatric and adult ALL, AML, CML in chronic/accelerated phase, Hodgkin lymphoma, aggressive and indolent NHL, and newly diagnosed multiple myeloma.
• RELAPSED OR REFRACTORY DISEASE: Patients who have failed one or more prior lines of therapy and require salvage regimens (e.g., R-ICE, R-DHAP, ESHAP for lymphoma; azacitidine or venetoclax-based combinations for AML) or access to CAR-T cell therapy (axicabtagene ciloleucel, tisagenlecleucel) or bispecific T-cell engager therapy.
• STEM CELL TRANSPLANT CANDIDATES: Patients with AML, ALL, CML, MDS, or chemosensitive relapsed lymphoma eligible for myeloablative or reduced-intensity conditioning (RIC) allogeneic HSCT, or autologous HSCT for myeloma and relapsed Hodgkin/NHL.
• REQUIRED DIAGNOSTICS BEFORE TRAVEL: Complete blood count (CBC) with differential and peripheral blood smear; bone marrow aspirate and trephine biopsy with immunohistochemistry (IHC); flow cytometry for immunophenotyping (CD markers panel); cytogenetics — conventional karyotype and FISH; molecular studies — BCR-ABL1 PCR (CML/ALL), FLT3/IDH1/IDH2/NPM1/CEBPA mutation panel (AML), JAK2/CALR/MPL (MPN); NGS panel (hematologic malignancies); serum protein electrophoresis (SPEP), immunofixation, free light chain assay (for myeloma); CT-PET scan (whole body, for lymphoma staging); MRI spine/brain (if CNS involvement suspected); ECHO/echocardiography (pre-anthracycline therapy cardiotoxicity baseline); HLA typing (for allogeneic HSCT candidates and potential sibling donors); Liver function tests, renal function panel, viral serology (HIV, HBV, HCV, CMV, EBV — mandatory pre-transplant).
• +1 more

Chemotherapy Protocols (standard OF CARE)

Induction, consolidation, and maintenance chemotherapy remain the backbone of blood cancer treatment. Regimens are protocol-driven and disease-specific:

• Acute Myeloid Leukemia (AML): Standard '7+3' induction (cytarabine continuous infusion × 7 days + daunorubicin × 3 days); for FLT3-mutated AML, midostaurin is added (RATIFY protocol); IDH1/IDH2-mutated AML is treated with ivosidenib or enasidenib as targeted agents in frontline or relapsed settings. Gemtuzumab ozogamicin (GO) is incorporated in CD33-positive favorable-risk AML.
• Acute Lymphoblastic Leukemia (ALL): HyperCVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone) alternating with high-dose methotrexate/cytarabine; for Philadelphia chromosome-positive ALL (BCR-ABL1+), a second-generation TKI (dasatinib or ponatinib) is mandatory. Blinatumomab (CD19/CD3 bispecific) and inotuzumab ozogamicin (CD22-targeted) are used in MRD-positive or relapsed/refractory ALL, supported by CNS prophylaxis via intrathecal methotrexate/cytarabine.
• Chronic Myeloid Leukemia (CML): First-line tyrosine kinase inhibitor (TKI) therapy — imatinib (generic, affordable), dasatinib, nilotinib, or bosutinib (second-generation); ponatinib or asciminib for T315I-mutant or TKI-resistant disease. Deep molecular response (DMR) monitoring by BCR-ABL1 PCR (IS) is performed at 3, 6, and 12 months to guide TKI continuation, switch, or potential treatment-free remission (TFR) attempt.
• Hodgkin Lymphoma: ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for early/intermediate stages; escalated BEACOPP for advanced-stage high-risk disease; brentuximab vedotin (BV) + AVD replacing bleomycin in high-risk advanced HL based on ECHELON-1 data. PET-adapted response evaluation guides escalation or de-escalation.
• Non-Hodgkin Lymphoma (Aggressive — DLBCL): R-CHOP (rituximab + CHOP) remains standard; polatuzumab vedotin-R-CHP (Pola-R-CHP) for high-IPI DLBCL based on POLARIX trial. Relapsed/refractory: R-ICE or R-DHAP salvage → autologous HSCT if chemosensitive; CAR-T (axicabtagene, tisagenlecleucel, lisocabtagene) for third-line and beyond.
• Follicular Lymphoma (Indolent NHL): Rituximab monotherapy or BR (bendamustine + rituximab); obinutuzumab-based combinations; lenalidomide + rituximab (R²); PI3K inhibitors (copanlisib, umbralisib) for relapsed disease.
• Multiple Myeloma: Frontline triplet VRd (bortezomib + lenalidomide + dexamethasone) or DRd (daratumumab + lenalidomide + dexamethasone) per MAIA trial; transplant-eligible patients proceed to autologous HSCT after 4–6 cycles of induction. Novel quadruplet induction (Dara-VRd) is now standard at high-volume centers. Relapsed myeloma: carfilzomib-based triplets, pomalidomide combinations, elotuzumab, isatuximab, selinexor, belantamab mafodotin, or teclistamab (BCMA-CD3 bispecific).

Hematopoietic STEM CELL Transplantation (HSCT)

PHASE 1 — Pre-arrival & Remote Consultation (WEEKS 1–2)

• GAF Healthcare case coordinator collects all existing pathology, biopsy, and molecular reports and submits to the designated hematologist-oncologist in India or UAE for remote multidisciplinary tumor board (MDT) review.
• Second-opinion report, proposed treatment protocol, and itemized cost estimate issued within 5–7 business days.
• Medical visa (India: e-Medical Visa, single or multiple entry) or UAE entry visa facilitated by GAF Healthcare; standard processing 3–5 business days.
• Travel itinerary, airport pickup, and pre-selected hospital-proximate accommodation arranged for patient and one attendant.

PHASE 2 — Arrival & Diagnostic Confirmation (DAYS 1–5)